

## Impaired glucose metabolism in irritable bowel syndrome: personalised low-glycaemic diet as potential therapeutic target

We read with great interest the recent study by Gilliam-Vigh *et al* demonstrating significant transcriptomic alterations in the intestinal mucosa of individuals with type 2 diabetes (T2D), particularly increased immune activation, altered barrier function in the large intestine and metabolic dysfunction.<sup>1</sup> These findings provide crucial mechanistic insights that complement observations on metabolic disturbances in patients with irritable bowel syndrome (IBS), supporting the rationale for glucose-targeted interventions.

### PERSONALISED LOW-GLYCAEMIC DIET: A NOVEL THERAPEUTIC APPROACH

Given the substantial interindividual variability in glycaemic responses,<sup>2</sup> we investigated the therapeutic potential of a personalised low-glycaemic diet (PLGD) in IBS management. In our nutritional

observation study of 20 age and gender-matched patients with IBS, we compared clinical outcomes between those receiving either a PLGD or the established low-FODMAP diet (LFD) over a minimum 3-month period (figure 1).

Remarkably, our personalised nutrition (PN) approach achieved symptom improvement comparable to standard LFD, assessed by the validated IBS Severity Scoring System (IBS-SSS) (online supplemental material). PLGD showed a −100 point reduction in IBS-SSS ( $p=0.0195$ ), comparing favourably to published data from Nybacka *et al*, where LFD plus dietary advice reduced scores by −117 points, and a low-carbohydrate diet achieved −93 points.<sup>3</sup>

### MECHANISTIC RATIONALE


The mechanistic basis for targeting glucose metabolism in IBS is supported by several converging lines of evidence. IBS pathophysiology is characterised by gut-brain axis dysregulation, involving interactions among the central and enteric nervous systems, gut microbiota and mucosal immune system.<sup>4</sup> Impairments in glucose metabolism observed in patients with IBS suggest glycaemic control as a promising therapeutic target that may influence several of these pathways simultaneously.

Furthermore, the transcriptomic signature described by Gilliam-Vigh *et al* in patients with T2D mirrors pathophysiological features observed in IBS. This convergence points to the metabolic-immune axis as a shared pathogenic mechanism across both disorders. Importantly, hyperglycaemia itself drives intestinal barrier dysfunction and increases infection risk,<sup>5</sup> providing direct mechanistic support for glucose-targeted interventions in functional GI disorders.

The regional specificity of transcriptomic changes is particularly noteworthy. The reported immune activation in the ileocaecal region and large intestine corresponds to the anatomical loci most frequently implicated in IBS symptomatology. This regional vulnerability may explain why targeting glucose metabolism through PN yields symptomatic benefit across distinct IBS phenotypes.

### CLINICAL IMPLICATIONS AND FUTURE DIRECTIONS

PLGD offers several clinical advantages over traditional dietary strategies. Unlike LFD, which may reduce beneficial short-chain fatty acid production and adversely affect GI microbiota composition and cardiometabolic risk profile with



**Figure 1** Precomparison and postcomparison in IBS Severity Scoring System (IBS-SSS) between age- and gender-matched patients with IBS receiving either a personalised low-glycaemic diet (PLGD, n=10) or a standard therapy low in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) diet (LFD, n=10) using paired Wilcoxon test. The group means are represented by a dashed line, and an arrow represents the reduction in IBS-SSS, with a reduction between 50 and 230 points in PLGD and between 30 and 290 points in LFD. \*P<0.05.

long-term use,<sup>6</sup> PLGD could maintain dietary diversity while optimising individual metabolic responses.

Our approach used a 2-week self-directed test phase with continuous glucose monitoring (CGM), followed by app-based dietary recommendations, eliminating the need for intensive dietary counselling while accommodating individual food preferences and intolerances. This approach addresses key limitations of current dietary interventions: the need for specialised dietary counselling, restricted food choices and potential long-term cardiovascular and microbiome alterations.

The integration of CGM with digital therapeutic platforms offers a scalable, personalised approach to IBS management that could be widely implemented in clinical practice. This PN strategy aligns with the growing recognition that ‘one-size-fits-all’ dietary recommendations have limited efficacy in heterogeneous conditions like IBS.

## CONCLUSION

Our findings suggest that patients with IBS exhibit impaired glucose metabolism and that PLGD can achieve therapeutic benefits comparable to established treatments. The mechanistic insights provided by Gilliam-Vigh *et al* underscore the role of metabolic-immune interactions. Combined with evidence that hyperglycaemia could drive intestinal barrier dysfunction, these findings establish a compelling rationale for targeting glucose metabolism in IBS. Therefore, PN, targeting individual glycaemic

responses, may represent a paradigm shift in functional GI disorder management, offering both mechanistic rationale and practical advantages over current dietary interventions.

**Franziska Schmelter** ,<sup>1</sup> **Torsten Schröder**,<sup>1,2</sup> **Yves Laumonier**,<sup>1</sup> **OUTLIVE-CRC consortium**, **Stephan C Bischoff** ,<sup>3</sup> **Stefanie Derer** ,<sup>1</sup> **Benjamin Anderschou Holbech Jensen** ,<sup>4</sup> **Christian Sina**<sup>1</sup>

<sup>1</sup>Institute of Nutritional Medicine, University Hospital Schleswig-Holstein Lübeck Campus, Lübeck, Germany

<sup>2</sup>Perfood Laboratories GmbH, Lübeck, Germany

<sup>3</sup>Institute of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany

<sup>4</sup>Department of Biomedical Sciences, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark

**Correspondence to** Dr Franziska Schmelter; Franziska.Schmelter@uksh.de

**Collaborators** OUTLIVE-CRC consortium: Alexander Katalinic (UKSH Lübeck/University of Lübeck), Martina Oberländer (University of Lübeck), Ruth Deck (University of Lübeck), Stefanie Derer (UKSH Lübeck), Holger Sülthmann (DKFZ Heidelberg), Nikolas von Bubnoff (UKSH Lübeck), Timo Gemoll (UKSH Lübeck), Hauke Busch (UKSH Lübeck/University of Lübeck), Peter Jülg (Hahn-Schickard Society Freiburg), Tobias Hutzenlaub (Hahn-Schickard Society Freiburg), Christian Sina (UKSH Lübeck), Torsten Schröder (Perfood Laboratories GmbH Lübeck), Dominik Burziwoda (Perfood Laboratories GmbH Lübeck).

**Contributors** Conceptualisation: FS, BAHJ, CS. Data curation: FS, TS, YL, CS. Formal analysis: FS, CS. Funding acquisition: OUTLIVE-CRC consortium, SCB, SD, CS. Investigation: FS, TS, YL, SD, CS. Methodology: FS, TS, SD, CS. Project administration: CS. Resources: TS, YL, OUTLIVE-CRC consortium, SD, CS. Supervision: BAHJ, CS. Validation: FS, CS. Visualisation: FS. Writing—original draft preparation: FS, BAHJ, CS. Writing—review and editing: TS, SCB, YL, SD. All authors have read and agreed to the published version of the manuscript.

**Funding** This work was supported by the German Federal Ministry of Research, Technology and Space (01KD2103A and 01EA2109A).

**Disclaimer** The views presented in this manuscript are those of the authors and not necessarily those of the company.

**Competing interests** TS is employed at Perfood Laboratories GmbH. TS is a co-founder of Perfood Laboratories GmbH and a minority shareholder.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and data collection was conducted under the framework of the ‘OUTLIVE-CRC study’, which was approved by the Ethics Committee of the University of Lübeck (AZ 21-415) and registered in the German Clinical Trials Register (DRKS00031028). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.



## OPEN ACCESS

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on

different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/gutjnl-2025-336797>).



**To cite** Schmelter F, Schröder T, Laumonnier Y, *et al.* *Gut* 2026;**75**:1081–1083.

Received 25 August 2025

Accepted 24 September 2025

Published Online First 5 October 2025

*Gut* 2026;**75**:1081–1083. doi:10.1136/gutjnl-2025-336797

#### ORCID iDs

Franziska Schmelter <https://orcid.org/0009-0009-0649-675X>

Stephan C Bischoff <https://orcid.org/0000-0003-2614-5948>

Stefanie Derer <https://orcid.org/0000-0002-6142-5577>

Benjamin Anderschou Holbech Jensen <https://orcid.org/0000-0001-6991-0828>

#### REFERENCES

- 1 Gilliam-Vigh H, Ellegaard AM, Madsen MR, *et al.* Mucosal transcriptomic landscape along the small and large intestines in individuals with and without type 2 diabetes. *Gut* 2026;**75**:33–45.
- 2 Zeevi D, Korem T, Zmora N, *et al.* Personalized Nutrition by Prediction of Glycemic Responses. *Cell* 2015;**163**:1079–94.
- 3 Nybacka S, Törnblom H, Josefsson A, *et al.* A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial. *Lancet Gastroenterol Hepatol* 2024;**9**:507–20.
- 4 Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. *Gastroenterology* 2016;**150**:1257–61.
- 5 Thaïss CA, Levy M, Grosheva I, *et al.* Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. *Science* 2018;**359**:1376–83.
- 6 Staudacher HM, Lomer MCE, Anderson JL, *et al.* Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. *J Nutr* 2012;**142**:1510–8.